☆
Watchlist
Log in
Sign-up
JAYEX Technology Ltd (jtl) Logo

JAYEX Technology Ltd (JTL)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

JTL Chart

Snapshot

JTL's Principal Activity is the development and provision of healthcare industry service technologies and the development of integrated dispensing automation systems for the pharmaceutical and healthcare sectors.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -75.89%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 2,380 of 2,408
Sector Rank 206 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies HHI / MGZ / EZZ
EPS -$0.018
DPS $0.00
Book Value Per Share $0.01

Broker Consensus

JTL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Jayex Technology Limited (JTL, formerly Jayex Healthcare Limited) is a provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's five interconnected and proprietary technologies. The products/services are: Enlighten patient workflow platform; Appointuit patient engagement solution; Pharmacy Delivery 2 U prescription delivery service; BluePoint remote pharmacy prescription processing and dispensing terminal; and the Jayex Connect - the complete cloud-based Patient Engagement Platform.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Milton QLD 4064
Website www.jayex.com/en-au/
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 17 Dec 2015

Upcoming Calendar (Forecasted)

Date Event
15/08/2022 Report (Annual)
31/08/2022 Report (Interim)
28/02/2023 Report (Prelim)
31/03/2023 Report (Prelim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Nicholas Harper Non-Executive Director Sep 2020

Mr Nicholas Harper

Non-Executive Director

Mr Harper has over thirty years' experience working in software development. During that time, he has worked in the public sector (local government), investment banking and the aviation sector in a wide variety of roles and with varied responsibilities. Nick has worked on implementing and maintaining many different types of software systems from batch valuation systems to real-time data processing. Based in the UK, He also has experience of project management and software team building.

Mr Michael Denis Boyd Executive Chairman,Executive Director May 2017

Mr Michael Denis Boyd

Executive Chairman,Executive Director

Mr Boyd is the Chairman of the Company and has been involved since its inception in 2004. Based in Melbourne, he has led the corporate structuring of the Company and the development of the Group's strategic vision. On a practical level he has initiated contacts with all stakeholder groups including professional bodies, regulatory boards, wholesale distributors and pharmacy groups and individuals. Mr. Boyd has been involved in the creation of new enterprises, both in the private and public sectors, for over 27 years. Mr. Boyd has been successful in developing and growing new projects in diverse areas including healthcare, telecommunications and finance. Trained as a Chartered Accountant, he was a founding Director and Chairman of Sonic Healthcare Ltd, now an ASX listed top 50 company. After leaving Sonic he started Foundation Healthcare, growing it to over 800 healthcare professionals before it was acquired by Sonic. He was also a founding partner of Iridium Satellite bringing it out from bankruptcy to now a NASDAQ listed company.
Mr Michael Chan Non-Executive Director Mar 2017

Mr Michael Chan

Non-Executive Director

Mr Chan has experience in broad based financial services for the past 30 years with hands on knowledge in both consumer and commercial sectors of the business. Michael is the founder and Managing Director at AMG Corporate Pty Ltd, a holder of an Australian Credit Licence which is primarily a debt advisory business. Prior to establishing AMG, Michael worked in key roles involved with strategic business development and marketing at several companies, both in the private and public sectors. Mr Chan has had a past affiliation with Make a Wish Foundation and more recently is the founder and chairman of The Mate Foundation - a men's health initiative with its principal purpose to help raise awareness of men's health diseases, which is due to launch shortly. He has over the years also undertaken philanthropic work for various other charities and causes in his community.
Ms Melanie Jaye Leydin Company Secretary Aug 2015
Mr Brian Renwick Non-Executive Director Jul 2009

Mr Brian Renwick

Non-Executive Director

Mr. Renwick is experienced across the pharmaceutical and healthcare sector in Australia. His involvement with sector commenced in finance roles that led into commercial analysis, marketing and sales. From this broad commercial experience in the manufacturing end of the supply chain he moved into the wholesaling with various business development roles in retail and hospital pharmacy. Mr Renwick's roles broadened into commercial and business development including as general manager for a corporate pharmacy business. He has completed two Business Development roles within the CSL Limited group. With his detailed commercial knowledge and broad experience across the healthcare sector, Brian has provided consulting advice to Jayex since 2006 and is an important member of the team.
Nathan Woodard Chief Financial Officer N/A
Show All

Director Transactions

JTL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
22/09/21 Michael Chan Issued 624,545 $0.025 $15,613 Rights issue
22/09/21 Michael Boyd Issued 26,970,970 $0.025 $674,274 Rights issue
22/09/21 Brian Renwick Issued 415,218 $0.025 $10,380 Rights issue
30/06/21 Michael Chan Buy +20,000 $0.027 $539 On-market trade
Show All

Director Interests

The current holdings of JTL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Michael Chan 31/12/2021 N/A 2,498,180 N/A N/A
Brian Renwick 31/12/2021 1,660,871 N/A N/A N/A
Michael Boyd 31/12/2021 N/A 107,883,880 N/A N/A
Nicholas Harper 02/09/2020 0 N/A N/A N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Mar 28, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Covenant Holdings(Wa)Pty Ltd <Boyd#4 A/C> 103,883,880 41.68%
Vector London Ltd 19,003,378 7.62%
Mr Joel David Webb 5,100,000 2.05%
Bodie Investments Pty Ltd 5,000,000 2.01%
Twin Oaks Super Pty Ltd <Twin Oaks Super Fund A/C> 5,000,000 2.01%
Mr Jeremy Ruben & Mrs Vanessa Ruben <Jvr Super Fund A/C> 4,338,067 1.74%
Mr Dean Henry Cleary <The Clearway Investment A/C> 4,140,000 1.66%
Covenant Holdings (Wa) Pty Ltd <The Boyd No 3 A/C> 4,000,000 1.61%
Rhyd-Y-Felin Pty Ltd 3,000,000 1.20%
Mr John Clive Allinson 2,900,000 1.16%
Donovan Products Pty Ltd <Family Account> 2,746,916 1.10%
Mr Mun Kee Chang 2,651,433 1.06%
Amg Corporate Pty Ltd <The Amg Super Fund A/C> 2,498,180 1.00%
Ms Pharoth San & Mr Kaden San <Pksan Superfund A/C> 2,372,651 0.95%
Ms Chunyan Niu 2,000,000 0.80%
R & F Mantel Pty Ltd <R & F Mantel Super Fund A/C> 1,700,000 0.68%
Sherkane Pty Ltd 1,666,667 0.67%
Mr Brian Patrick Renwick 1,660,871 0.67%
Mr Peter Howells 1,558,243 0.63%
Yavern Creek Holdings Pty Ltd 1,428,572 0.57%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 20 34 89 246 177 566

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Vector London Ltd 28/03/2022 19,003,378 7.62
Covenant Holdings (WA) Pty Ltd 28/03/2022 103,883,880 41.68

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
22-09-21 Michael Boyd and Covenant Holdings (WA) Pty Ltd 26,970,970 36.70 43.29
04-06-21 Michael Boyd and Covenant Holdings (WA) Pty Ltd 1,714,831 45.77 41.93

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.025 30 June
JTL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.